Natural History Studies of Mucopolysaccharidosis III
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02037880|
Recruitment Status : Completed
First Posted : January 16, 2014
Last Update Posted : November 16, 2015
|Condition or disease||Intervention/treatment|
|Mucopolysaccharidosis Type IIIA Mucopolysaccharidosis Type IIIB||Procedure: Lumbar puncture Device: Magnetic Resonance Imaging (MRI) of the brain|
Mucopolysaccharidosis (MPS) type III (Sanfilippo syndrome) is a group of four devastating genetic diseases that result in the abnormal accumulation of glycosaminoglycans in body tissues. In MPSIII the predominant symptoms occur due to accumulation within the central nervous system (CNS), including the brain and spinal cord, resulting in cognitive decline, motor dysfunction, and eventual death.
In anticipation for future therapeutic studies for MPSIIIA and MPSIIIB, we are performing a natural history study to identify the following:
- Individual rates of decline in motor and cognitive function in a cohort of potential clinical trial patients
- The natural history of outcome measures in order to assess their appropriateness as outcomes in an eventual trial
- Baseline functional data in patients who will be potential candidates for an eventual trial
- Biomarkers of disease progression over a 12-month interval, including changes in brain MRI and in cerebrospinal fluid
Patients in this study will need to come to Nationwide Children's Hospital in Columbus, Ohio, three times. At each of these three time points, cognitive outcome measures will be assessed: at baseline (visit 1), 6 months (visit 2), and at 12 months (visit 3). At baseline (visit 1) and 12 months (visit 3), an MRI and a lumbar puncture will be performed.
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Official Title:||Natural History Studies of Mucopolysaccharidosis III|
|Study Start Date :||February 2014|
|Primary Completion Date :||November 2015|
|Study Completion Date :||November 2015|
MPS IIIA/B Subjects
Cohort will be followed for one year to assess natural history of the disease.
|Procedure: Lumbar puncture Device: Magnetic Resonance Imaging (MRI) of the brain|
- Cognitive function [ Time Frame: up to 12 months ]Assessed using the Leiter International Performance assessment, a non-verbal assessment of cognitive function.
- Adaptive functioning [ Time Frame: Months 0, 6, and 12 ]Parental assessment of adaptive functioning using the Adaptive Behavioral Assessment System
- Emotional/behavioral function [ Time Frame: Months 0, 6, and 12 ]Assessment of emotional/behavioral problems using the Child Behavioral Checklist
- White and grey matter brain volumes [ Time Frame: Months 0 and 12 ]Assessment of brain volumes by MRI. MRI will be performed under sedation.
- Serum and cerebrospinal fluid NAGLU (MPSIIIB subjects) or SGSH (MPSIIIA subjects) levels [ Time Frame: Months 0 and 12 ]Measurement of NAGLU or SGSH activity in serum (by venipuncture) and CSF (by lumbar puncture). Lumbar puncture will be performed under sedation.
- Liver size [ Time Frame: Months 0 and 12 ]Liver volume will be assessed by abdominal MRI obtained under the same sedation event as brain MRI and lumbar puncture.
Biospecimen Retention: Samples With DNA
Biobanking will include:
- Cerebrospinal fluid
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02037880
|United States, Ohio|
|Nationwide Children's Hospital|
|Columbus, Ohio, United States, 43205|
|Principal Investigator:||Kevin M Flanigan, MD||Nationwide Children's Hospital, Columbus, Ohio|